• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

添加促动力药对质子泵抑制剂(PPI)抵抗的非糜烂性反流病(NERD)患者的疗效:GERD症状频率量表(FSSG)在治疗策略决策中的意义。

Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.

作者信息

Miyamoto Masaki, Manabe Noriaki, Haruma Ken

机构信息

Department of General Internal Medicine, Prefectural Hiroshima Hospital, Hiroshima.

出版信息

Intern Med. 2010;49(15):1469-76. doi: 10.2169/internalmedicine.49.3615. Epub 2010 Aug 2.

DOI:10.2169/internalmedicine.49.3615
PMID:20686276
Abstract

BACKGROUND

Non-erosive reflux disease (NERD) is a more difficult to treat than reflux esophagitis (RE) due to the high prevalence of PPI resistance. Consequently, the treatment strategy for NERD is yet to be established.

PATIENTS AND METHODS

Subjects were 467 GERD patients (NERD 349, RE 118, 47.4 +/- 16.7 years) with reflux symptoms such as heartburn. PPI was administered for 2 weeks, and total score (TS) of symptoms, seven items of reflux symptoms e.g. heartburn (reflux score: RS), and five items of dyspeptic symptoms e.g. heavy stomach (dyspeptic score: DS) were assessed using the frequency scale for the symptoms of GERD (FSSG), a GERD-specific questionnaire developed in Japan. Improvement <50% in TS was defined as non-responder. Patients' background, and pretreatment TS, RS, DS, and 12 items of FSSG were assessed. Furthermore, the effect of additional prokinetics (4 weeks) for 117 PPI non-response NERD patients was also examined.

RESULTS

Younger age, constipation, higher TS, DS, F2 (bloated stomach), 3 (heavy stomach), 5 (sick feeling after meal), 8 (satiety during meal) in FSSG were factors to be PPI non-responders in NERD. Significant improvement in TS were observed (pretreatment: 17.4 +/- 7.7 vs. 2 weeks 14.6 +/- 6.0 vs. 6 weeks 7.7 +/- 5.2, p<0.0001) after the addition of prokinetics in PPI non-response NERD.

CONCLUSION

Younger age, constipation, dysmotility were factors of PPI non-response in NERD. As high DS is correlated with PPI non-response, it is indicated that patients with strong dysmotility and functional dyspepsia complication might be PPI resistant. The efficacy of additional prokinetics for PPI non-response NERD was observed.

摘要

背景

由于质子泵抑制剂(PPI)抵抗的高发生率,非糜烂性反流病(NERD)比反流性食管炎(RE)更难治疗。因此,NERD的治疗策略尚未确立。

患者与方法

研究对象为467例有烧心等反流症状的胃食管反流病(GERD)患者(NERD 349例,RE 118例,年龄47.4±16.7岁)。给予PPI治疗2周,使用日本开发的GERD特异性问卷——GERD症状频率量表(FSSG)评估症状总分(TS)、7项反流症状如烧心(反流评分:RS)以及5项消化不良症状如胃部沉重感(消化不良评分:DS)。TS改善<50%定义为无反应者。评估患者的背景以及治疗前的TS、RS、DS和FSSG的12项指标。此外,还检查了117例PPI无反应的NERD患者加用促动力药(4周)的效果。

结果

年龄较小、便秘、TS、DS较高,FSSG中的F2(胃胀)、3(胃部沉重感)、5(餐后不适感)、8(进餐时饱腹感)是NERD中PPI无反应的因素。在PPI无反应的NERD患者中加用促动力药后,观察到TS有显著改善(治疗前:17.4±7.7,2周时:14.6±6.0,6周时:7.7±5.2,p<0.0001)。

结论

年龄较小、便秘、动力障碍是NERD中PPI无反应的因素。由于高DS与PPI无反应相关,提示动力障碍强且合并功能性消化不良的患者可能对PPI耐药。观察到加用促动力药对PPI无反应的NERD有效。

相似文献

1
Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.添加促动力药对质子泵抑制剂(PPI)抵抗的非糜烂性反流病(NERD)患者的疗效:GERD症状频率量表(FSSG)在治疗策略决策中的意义。
Intern Med. 2010;49(15):1469-76. doi: 10.2169/internalmedicine.49.3615. Epub 2010 Aug 2.
2
Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.质子泵抑制剂(PPI)抵抗的胃食管反流病患者的预处理预测研究及 PPI 剂量递增挑战-TORNADO 研究:日本酸相关症状研究组的一项多中心前瞻性研究。
J Gastroenterol. 2011 Nov;46(11):1273-83. doi: 10.1007/s00535-011-0446-2. Epub 2011 Aug 24.
3
Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.非糜烂性反流病中质子泵抑制剂治疗抵抗的流行率和临床特征。
Aliment Pharmacol Ther. 2018 Nov;48(10):1074-1081. doi: 10.1111/apt.14986. Epub 2018 Oct 7.
4
Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.比较莫沙必利联合奥美拉唑与奥美拉唑单药治疗胃食管反流病疗效的随机对照试验
J Dig Dis. 2014 Sep;15(9):469-76. doi: 10.1111/1751-2980.12167.
5
Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.来自G-PRIDE研究中对理气剂有反应的质子泵抑制剂难治性非糜烂性反流病老年患者的临床特征
BMC Gastroenterol. 2014 Jul 2;14:116. doi: 10.1186/1471-230X-14-116.
6
Pretreatment prediction of symptom response to proton pump inhibitor therapy.质子泵抑制剂治疗症状反应的预处理预测。
J Gastroenterol Hepatol. 2015 Mar;30 Suppl 1:25-30. doi: 10.1111/jgh.12744.
7
Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?质子泵抑制剂反应者,经阻抗和 pH 监测未被确认为 GERD 患者:他们是谁?
Neurogastroenterol Motil. 2014 Jan;26(1):28-35. doi: 10.1111/nmo.12221. Epub 2013 Aug 29.
8
Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.对经验性质子泵抑制剂治疗无效的烧心和上腹痛患者的算法处理方法。
Dig Dis Sci. 2011 Oct;56(10):2871-8. doi: 10.1007/s10620-011-1708-9. Epub 2011 Apr 22.
9
Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.沃克在反流性食管炎、非糜烂性食管炎及质子泵抑制剂抵抗的胃食管反流病初始及维持治疗中的疗效
Medicine (Baltimore). 2020 Mar;99(11):e19520. doi: 10.1097/MD.0000000000019520.
10
Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.多通道腔内阻抗-pH 监测引导下的个体化治疗难治性非糜烂性反流病。
Cell Death Dis. 2017 Sep 7;8(9):e3040. doi: 10.1038/cddis.2017.436.

引用本文的文献

1
Gastroesophageal Reflux Disease: Pathophysiology and New Treatment Trends.胃食管反流病:病理生理学和新的治疗趋势。
Intern Med. 2024 Jan 1;63(1):1-10. doi: 10.2169/internalmedicine.1551-23. Epub 2023 Mar 15.
2
2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease.《2020年胃食管反流病诊断与管理首尔共识》
J Neurogastroenterol Motil. 2021 Oct 30;27(4):453-481. doi: 10.5056/jnm21077.
3
A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease.
随机对照试验的系统评价与荟萃分析:质子泵抑制剂联合促动力药治疗胃食管反流病
J Neurogastroenterol Motil. 2021 Apr 30;27(2):165-175. doi: 10.5056/jnm20161.
4
Efficacy of the four weeks treatment of omeprazole plus mosapride combination therapy compared with that of omeprazole monotherapy in patients with proton pump inhibitor-refractory gastroesophageal reflux disease: a randomized controlled trial.奥美拉唑联合莫沙必利四周治疗与奥美拉唑单药治疗质子泵抑制剂难治性胃食管反流病患者的疗效比较:一项随机对照试验
Clin Exp Gastroenterol. 2019 Jul 26;12:337-347. doi: 10.2147/CEG.S214677. eCollection 2019.
5
Evaluation of the Additive Effect of Domperidone on Patients with Refractory Gastroesophageal Reflux Disease; A Randomized Double Blind Clinical Trial.多潘立酮对难治性胃食管反流病患者的附加效应评估;一项随机双盲临床试验。
Middle East J Dig Dis. 2019 Jan;11(1):24-31. doi: 10.15171/mejdd.2018.124. Epub 2018 Nov 14.
6
Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.沃克对于质子泵抑制剂抵抗的非糜烂性反流病患者胃食管反流症状的疗效
Intern Med. 2018 Sep 1;57(17):2443-2450. doi: 10.2169/internalmedicine.0492-17. Epub 2018 Mar 30.
7
A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.质子泵抑制剂无反应性胃食管反流病的药物治疗综述
Dis Esophagus. 2017 Sep 1;30(9):1-15. doi: 10.1093/dote/dox055.
8
Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.接受质子泵抑制剂维持治疗的患者中与残留胃食管反流病症状相关的因素。
World J Gastroenterol. 2017 Mar 21;23(11):2060-2067. doi: 10.3748/wjg.v23.i11.2060.
9
Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.沃克(伏诺拉生)治疗非糜烂性胃食管反流病患者的疗效和安全性评估:一项III期、随机、双盲、安慰剂对照、多中心研究。
Curr Ther Res Clin Exp. 2016 Dec 21;81-82:1-7. doi: 10.1016/j.curtheres.2016.12.001. eCollection 2016.
10
Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA.胃食管反流病患者对质子泵抑制剂治疗的部分反应:美国患者特征、疾病负担及成本的观察性研究
Pragmat Obs Res. 2012 Dec 5;3:57-67. doi: 10.2147/POR.S36704. eCollection 2012.